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Adaptive -Cell Proliferation Is Severely Restricted With
Advanced Age
Matthew M. Rankin and Jake A. Kushner
OBJECTIVE—Regeneration of the insulin-secreting -cells is a
fundamental research goal that could beneﬁt patients with either
type 1 or type 2 diabetes. -Cell proliferation can be acutely
stimulated by a variety of stimuli in young rodents. However, it is
unknown whether this adaptive -cell regeneration capacity is
retained into old age.
RESEARCH DESIGN AND METHODS—We assessed adap-
tive -cell proliferation capacity in adult mice across a wide
range of ages with a variety of stimuli: partial pancreatectomy,
low-dose administration of the -cell toxin streptozotocin, and
exendin-4, a glucagon-like peptide 1 (GLP-1) agonist. -Cell
proliferation was measured by administration of 5-bromo-2-
deoxyuridine (BrdU) in the drinking water.
RESULTS—Basal -cell proliferation was severely decreased
with advanced age. Partial pancreatectomy greatly stimulated
-cell proliferation in young mice but failed to increase -cell
replication in old mice. Streptozotocin stimulated -cell replica-
tion in young mice but had little effect in old mice. Moreover,
administration of GLP-1 agonist exendin-4 stimulated -cell
proliferation in young but not in old mice. Surprisingly, adaptive
-cell proliferation capacity was minimal after 12 months of age,
which is early middle age for the adult mouse life span.
CONCLUSIONS—Adaptive -cell proliferation is severely re-
stricted with advanced age in mice, whether stimulated by partial
pancreatectomy, low-dose streptozotocin, or exendin-4. Thus,
-cells in middle-aged mice appear to be largely postmitotic.
Young rodents may not faithfully model the regenerative capacity
of -cells in mature adult mice. Diabetes 58:1365–1372, 2009

-Cell mass normally grows well into adulthood to
provide increased insulin secretion capacity to
match the greater insulin requirements of maturity
(1,2). -Cell mass can slowly expand in adult
rodents in response to increased insulin require-
ments (3) or during pregnancy (4). Several mechanisms
have been invoked to explain adult -cell mass expansion,
including neogenesis from pancreatic ducts or hematopoi-
etic tissues, replication of specialized -cell progenitors,
and self-renewal by -cells (5–7). However, the ﬁndings of
recent studies by several groups (including ours) indicate
that normal -cell growth primarily occurs by self-renewal
of mature -cells—not by replication of specialized pro-
genitors (8–12). This regenerative capacity has prompted
speculation that regeneration of -cell function might
someday be possible in adult patients with diabetes (8).
However, -cell regeneration has proven to be an ambi-
tious and elusive goal. Sadly, expansion of bona ﬁde
human -cells has not been convincingly demonstrated
(13–15). Why is -cell regeneration easily stimulated in
rodents, yet difﬁcult to achieve in humans? Is rodent -cell
replication regulated in fundamentally different ways com-
pared with that of humans? Or is mammalian -cell
replication limited by unrealized factors? Could age be a
factor?
In the past, rodent -cells were widely assumed to have
a very short life span and to require ongoing turnover
(3,16). In contrast, we recently discovered that aged mice
have very little evidence of -cell turnover (17). We
therefore hypothesized that cell cycle entry of -cells
could be restricted with age. To test this hypothesis, we
investigated -cell regeneration as a function of age in
adult mice. Here, we show that adaptive -cell prolifera-
tion capacity is severely restricted with advanced age.
RESEARCH DESIGN AND METHODS
All experiments with mice were performed in the animal facility at The
Children’s Hospital of Philadelphia according to the guidelines of the Institu-
tional Animal Care and Use Committee (IACUC). The ﬁrst set of experiments
included male F1 hybrid B6129SF1/J mice (stock 101043), obtained at 1 and 8
months of age from The Jackson Laboratory (Bar Harbor, ME). The Jackson
B6129SF1/J hybrid is the product of an intercross between C57BL/6J (000664)
female mice and 129S1/SvImJ (002448) male mice from The Jackson Labora-
tory’s commercial colonies. The second set of experiments used male F1
hybrid B6129SF1/J mice obtained at 1 month of age from the Taconic Farms
(Hudson, NY). The Taconic B6129F1 hybrid model is the product of an
intercross between C57BL/6NTac (black 6) female mice and 129S6/SvEvTac
(129S6) male mice from Taconic commercial colonies.
Partial pancreatectomy. Partial pancreatectomy was performed, as previ-
ously reported (9). The splenic portion of the pancreas was surgically
removed, resulting in an 50% pancreatectomy. A sham operation was
performed by opening the abdomen but leaving the pancreas intact.
Low-dose streptozotocin administration and exendin-4 treatment. Mice
received ﬁve daily injections of low-dose (30 mg/kg) streptozotocin using
established protocols (9,18–21). Exendin-4 was administered as previously
described (9). Mice were injected daily with 24 nmol/kg body wt in the
subcutaneous space daily for 21 days.
Statistics. All results are reported as means  SE for equivalent groups.
Results were compared with independent Student’s t tests (unpaired and
two-tailed) reported as P values.
Proliferation analysis. Mice were continuously labeled with 5-bromo-2-
deoxyuridine (BrdU) for 14 days after partial pancreatectomy or low-dose
streptozotocin or for 21 days during exendin-4 treatment before they were
killed. BrdU was administered in drinking water at 1 mg/ml as previously
described (9). Paraformaldehyde-ﬁxed, parafﬁn-embedded sections were
stained with DAPI/insulin/BrdU or DAPI/insulin/BrdU/Ki67 as previously
described (9). Images were acquired from 10–20 islets per animal and
condition, which represented 900–4,000 -cells per animal. To measure Ki67,
images were acquired from more than 100–200 islets per animal and condi-
tion, which represented 4,000–8,000 -cells per animal. Acinar cell prolifera-
tion analysis was performed by acquiring 10 random images per animal as
previously described (17). In all but one group, the results represent the
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DIABETES, VOL. 58, JUNE 2009 1365average from four to seven animals (the partial pancreatectomy cohort at 19
months included only three mice). -Cell proliferation was calculated per day
by dividing BrdU-positive -cells by the labeling period (14 or 21 days) and
expressed as percent total per day.
Islet morphometry. -Cell area was quantiﬁed as previously described (9).
-Cell area was measured in all three groups of the partial pancreatectomy
experiment: sham-operated, pancreatectomy-removed (the splenic portion),
and residual (the duodenal portion) sections.
RT-PCR. Partial pancreatectomy or sham operation was performed on mice
of various ages. Five days later, islets were isolated from pools of at least four
mice and processed into cDNA as previously described (22). Real-time
quantitative dual ﬂuorescent–labeled ﬂuorescence resonance energy transfer
(FRET) PCR (50°C for 2 min and 95°C for 10 min, followed by 40 cycles of
95°C for 15 s and 60°C for 1 min) was performed with the ABI 7900 real-time
PCR thermal cycler (Applied Biosystems, Foster City, CA) to amplify triplicate
samples, comparing sample values with islet log10 dilution curves. Relative
gene product amounts were reported for each gene compared with cyclo-
phillin and conﬁrmed in separate studies with a large panel of control genes
(for primer sequences, see supplemental Table 1, available in an online
appendix at http://diabetes.diabetesjournals.org/cgi/content/full/db08-1198/
DC1). Results are reported from a single experiment with technical repeats
averaged and reported as means  SEM. Representative RT-PCR data were
conﬁrmed in an independent experiment with pools of islet mRNAs derived
from equivalent groups of mice.
Immunoblotting. Cells were lysed in Tween-20 buffer. Proteins were re-
solved on denaturing polyacrylamide gels, electrophoretically transferred to
polyvinylidine ﬂuoride (PVDF) membranes (Immobilon-P Transfer Mem-
brane; Millipore, Bedford, MA), and blotted with mouse anti-cyclin D2 ab-4
(Lab Vision, Thermo Fisher Scientiﬁc, Fremont, CA) and -tubulin (Santa Cruz
Biotechnology, Santa Cruz, CA).
RESULTS
Partial pancreatectomy is well tolerated in mice
across a wide range of ages. To test whether adaptive
-cell proliferation is restricted with age, we chose 50%
partial pancreatectomy, a robust model to induce -cell
proliferation (9). Partial pancreatectomy modestly re-
duces -cell mass while leaving sufﬁcient -cell function
for normal control of glucose homeostasis. As expected,
partial pancreatectomy was well tolerated across a wide
range of ages. Blood glucose values and postoperative
weight loss were equivalent in pancreatectomized and
sham-operated mice (Table 1). The resected portion of
pancreas comprised one-half of the total pancreatic weight
at each age-group (Table 2). Thus, splenic partial pancre-
actomy is a reliable and well-tolerated procedure in adult
mice of all ages.
Partial pancreatectomy is a robust stimulus of -cell
proliferation in young mice. We then tested whether
partial pancreatectomy stimulates -cell regeneration. To
detect all proliferation events during acute -cell regener-
ation, mice continuously received BrdU in the drinking
water for 2 weeks after pancreatectomy and were then
killed immediately. Partial pancreatectomy stimulated
-cell proliferation in mice aged 2 months (from 0.18 
0.05 to 1.80  0.36% per day after partial pancreatectomy;
TABLE 1
Partial pancreatectomy and high-dose exendin-4 treatment
Age
(months)
Body weight (g) in The Jackson Laboratory cohort
Sham operated (control) Partial pancreatectomy
Initial Final Change Initial Final Change P
2 30.9  1.1 25.6  1.4 5.3  0.5 30.2  0.9 26.0  0.8 4.2  0.2 0.387
8 38.1  1.1 33.0  0.4 5.1  0.7 36.9  1.4 31.9  1.5 5.0  0.4 0.307
12 42.2  2.5 35.7  1.7 6.5  1.5 41.7  2.5 33.3  0.9 8.0  2.4 0.914
14 45.3  2.6 37.1  1.7 8.2  1.1 36.4  6.6 28.2  4.7 8.1  2.4 0.749
19 48.9  2.4 44.7  2.2 4.1  0.9 46.9  4.0 40.6  3.5 4.4  0.7 0.923
Age
(months)
Blood glucose (mg/dl) in The Jackson Laboratory cohort
Sham operated (control) Partial pancreatectomy
Initial Final Average Initial Final P Average P
2 135  10 122  9 121  9 135  11 145  10 0.117 143  5 0.063
8 121  7 120  11 114  7 137  7 122  9 0.857 123  4 0.307
12 136  7 134  13 131  4 132  9 137  9 0.838 131  7 0.914
14 139  9 131  6 124  6 131  6 108  8 0.794 121  4 0.749
19 115  8 132  6 125  6 109  7 139  9 0.783 125  3 0.923
Age
(months)
Body weight (g) in the Taconic Farms cohort
Sham operated (control) Partial pancreatectomy
Initial Final Change Initial Final Change P
2 31.7  1.1 30.6  0.9 1.1  0.9 29.7  0.4 28.4  1.1 1.3  1.4 0.928
19 42.4  5.1 39.1  5.7 3.3  1.1 42.0  2.7 36.8  1.4 5.2  1.7 0.401
Age
(months)
Blood glucose (mg/dl) in the Taconic Farms cohort
Sham operated (control) Partial pancreatectomy
Initial Final Average Initial Final P Average P
2 134  12 126  12 128  8 127  7 132  11 0.117 131  7 0.570
19 94  9 100  11 98  88 6  9 103  11 0.783 92  5 0.605
Data are means  SEM for four to seven mice per group except the 19-month-old partial pancreatectomy cohort, which consisted of only
three mice. Body weight of mice before and 2 weeks after a sham operation (top left) or partial pancreatectomy (top right). Random-fed blood
glucose values for 2 weeks following sham operation or partial pancreatectomy, expressed as average values (middle left) or area under the
curve (middle right).
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stimulated -cell proliferation in mice aged 8 months
compared with control mice (from 0.08  0.02 to 1.06 
0.39% per day after partial pancreatectomy; P  0.04)
(Figs. 1 and 3). Notably, the change in total number of
BrdU-positive -cells (the absolute increase in -cell pro-
liferation) was less in mice aged 8 months than in mice
aged 2 months. Still, our results indicate that -cell regen-
eration capacity is retained well into maturity, even in
mice aged 8 months.
Minimal -cell proliferation in aged mice after partial
pancreatectomy. To test the hypothesis that -cell regen-
eration is restricted with advanced age, we analyzed -cell
proliferation in aged mice after partial pancreatectomy.
Surprisingly, partial pancreatectomy failed to stimulate
-cell proliferation in mice aged 19 months (from 0.03 
0.01 to 0.03  0.00% per day after partial pancreatectomy;
P  0.84) (Figs. 1 and 3). This result suggests that -cell
regeneration capacity could be very limited in aged mice.
Our data indicate that partial pancreatectomy–induced
-cell regeneration capacity is restricted in mice aged 19
months. To conﬁrm and reﬁne this observation, we re-
peated our studies with middle-aged mice. Interestingly,
mice aged 12 months displayed an intermediate pheno-
type. Partial pancreatectomy stimulated -cell prolifera-
tion in mice aged 12 months. However, the change in total
number of BrdU-positive -cells (the absolute increase in
-cell proliferation) was very small (from 0.03  0.01 to
0.25  0.09% per day after partial pancreatectomy; P 
0.03) (Figs. 1 and 3). Similar to results obtained in very old
mice, partial pancreatectomy failed to substantially in-
crease -cell proliferation in mice aged 14 months (from
0.02  0.01 to 0.05  0.02% per day after partial pancrea-
tectomy; P  0.31) (Figs. 1 and 3). Taken together, our
results illustrate that partial pancreatectomy–induced
-cell proliferation capacity is retained well into maturity.
However, partial pancreatectomy–induced -cell prolifer-
ation capacity is powerfully and abruptly restricted by
early middle age (12 months of age represent 40% of the
typical mouse life span) (23).
We then considered the possibility that partial pancrea-
tectomy might not adequately reduce -cell mass in aged
mice. In particular, we were concerned that unequal
distribution of -cells within the pancreas could inﬂuence
partial pancreatectomy–mediated -cell proliferation. If
-cell mass grew more rapidly in the head (duodenal) than
in the tail (splenic) with advanced age, removal of the
splenic portion of the pancreas might not efﬁciently reduce
-cell mass in aged mice. We quantiﬁed -cell mass
reduction after partial pancreatectomy, measuring -cell
area and -cell mass in pancreata of sham-operated (the
entire pancreas), resected (the splenic portion), and re-
maining (the duodenal portion) samples in each age
cohort. The total -cell area and -cell area mass contin-
uously increased with age in control mice (Table 2). -Cell
area and mass also continuously increased with age in
resected pancreata. Similarly, -cell area and mass contin-
uously increased in the remaining pancreata after partial
pancreatectomy. Moreover, -cell area and mass was
roughly equivalent in the resected and residual pancreata
of each age-group, indicating that partial pancreatectomy
reduced -cell mass by approximately one-half. Thus,
splenic partial pancreatectomy reduces -cell mass by
equivalent amounts in young and old mice. As a result,
-cell reduction by partial pancreatectomy should be a
robust stimulus of -cell regeneration in mice across all
ages.
Preserved acinar cell regeneration in aged mice. To
investigate whether regeneration of other pancreatic com-




2 8 12 14 19
Pancreatic weight (mg)
Sham operated (control) 253  13 301  19 ND 331  6 386  24
Partial pancreatectomy
Resected (splenic) 127  5 169  15 ND 184  3 187  9
Remaining (duodenal) 108  32 113  18 ND 204  6 212  27
-Cell area (%)
Sham operated (control) 0.61  0.09 0.85  0.17 ND 1.27  0.28 2.04  0.36
Partial pancreatectomy
Resected (splenic) 0.72  0.11 1.05  0.13 ND 1.90  0.61 2.60  0.61
Remaining (duodenal) 0.60  0.04 0.79  0.12 ND 1.28  0.20 2.07  0.55
-Cell mass (mg)
Sham operated (control)
Whole pancreas 1.57  0.26 2.46  0.41 ND 4.15  0.89 7.89  1.59
Partial pancreatectomy
Resected (splenic) 0.98  0.14 1.81  0.31 ND 3.48  1.12 4.76  1.07
Remaining (duodenal) 0.78  0.23 0.93  0.23 ND 2.59  0.36 4.72  1.75
Acinar proliferation (% BrdU/total)
Sham operated (control) 0.72  0.08 0.57  0.07 ND 0.41  0.07 0.53  0.11
Partial pancreatectomy 1.47  0.28 1.64  0.14 ND 1.62  0.24 1.07  0.1
P 0.04 0.0002 ND 0.001 0.02
Data are means  SEM for four to seven mice per group except the 19-month-old partial pancreatectomy cohort, which consisted of only
three mice. Data show pancreatic weight of sham-operated, resected, or remaining pancreas following partial pancreatectomy, expressed as
milligrams; -cell area of sham-operated, resected (splenic portion), or remaining pancreas (duodenal portion) following partial
pancreatectomy, expressed as percent total pancreas; -cell mass of sham-operated, resected, or remaining pancreas following partial
pancreatectomy, expressed as percent total pancreas; and acinar proliferation of sham-operated, resected, or remaining pancreas following
partial pancreatectomy, expressed as percent total pancreas. ND, not determined.
M.M. RANKIN AND J.A. KUSHNER
DIABETES, VOL. 58, JUNE 2009 1367regeneration after partial pancreatectomy. Conﬁrming pre-
vious reports, partial pancreatectomy robustly stimulated
occasional patches of acinar cell regeneration in very
young mice (from 0.72  0.08 to 1.47  0.28% per day after
partial pancreatectomy at 2 months of age; P  0.04)
(Table 2) (images not shown). Partial pancreatectomy also
stimulated acinar cell regeneration in very old mice aged
19 months (from 0.53  0.11 to 1.07  0.10% per day after
partial pancreatectomy; P  0.02) (Table 2). Similarly,
partial pancreatectomy stimulated acinar cell regeneration
at 8 months and 14 months of age (Table 2). These results
indicate that acinar replication capacity may not be inﬂu-
enced by age. Thus, age-dependent restriction of regener-
ation capacity of -cells is not common to all pancreatic
components.
Minimal -cell proliferation in aged mice after low-
dose streptozotocin. We then used the -cell toxin
streptozotocin to further test the hypothesis that -cell
regeneration capacity is restricted with advanced age.
Streptozotocin is a robust stimulus of -cell regeneration
when administered in multiple low doses to adult mice
(24). Low-dose streptozotocin was well tolerated and did
not cause hyperglycemia or extensive weight loss. As
expected, streptozotocin administration stimulated -cell
proliferation in mice aged 2 months by 0.36% per day
compared with controls (from 0.18  0.05 to 0.55  0.07%
per day after streptozotocin; P  0.003) (Figs. 2 and 3).
However, streptozotocin had little effect in aged mice:
-cell proliferation was only slightly increased in mice
aged 15 months compared with controls (from 0.02  0.01
to 0.04  0.01% per day after streptozotocin; P  0.17)
(Figs. 2 and 3).
Minimal -cell proliferation in aged mice after
exendin-4 treatment. We hypothesized that glucagon-
like peptide 1 (GLP-1)–stimulated -cell proliferation
might also be restricted in aged mice. To test this corollary
hypothesis, we treated mice with exendin-4, a GLP-1
agonist, using established protocols (9,18–21). Exendin-4
was fairly well tolerated and was not associated with
severe weight loss. Exendin-4 robustly stimulated -cell
proliferation in mice aged 2 months (0.76  0.07% per day
with exendin-4 treatment; P  0.00001 compared with
sham-operated controls) (Figs. 2 and 3). By contrast,
exendin-4 treatment resulted in little -cell proliferation in
14-month-old mice (0.08  0.03% per day with exendin
treatment; P  0.13 compared with sham-operated con-
trols) (Figs. 2 and 3). Notably, the change in total number
of BrdU-positive -cells’ (the absolute increase in -cell
proliferation) response to exendin-4 was 10-fold greater
in young mice than in old mice. Thus, GLP-1–stimulated
-cell regeneration is also restricted in aged mice.
Basal -cell proliferation declines in aged mice. The
observation that adaptive -cell proliferation is severely
restricted with advanced age implies that -cells could
undergo cell cycle exit as a function of age (equivalent to
cellular quiescence). To further test this hypothesis, we
compared basal (nonstimulated) -cell proliferation rates
in control mice across a range of ages. Conﬁrming our
previous observations (17), basal -cell proliferation de-
creased from 2 to 8 months (from 0.18  0.05 to 0.08 
0.02% per day; P  0.008) (Figs. 1 and 3). Basal -cell
proliferation further decreased by 12 months (to 0.03 
0.01% per day; P  0.03) and remained low in 14- and
19-month-old mice (P  0.01 at 14 months compared with
2 months; P  0.03 at 19 months compared with 2 months).
Thus, basal -cell proliferation was fully restricted by 12
months of age, which was rapidly followed by restriction
of partial pancreatectomy–induced -cell regeneration.
Minimal -cell proliferation in aged mice after partial
pancreatectomy in an independent genetic cohort.
Our studies on aging were initially performed with F1
hybrid B6129SF1/J mice from The Jackson Laboratory. We
chose this strain because it closely approximates the
mixed genetic background of laboratory knockout mice
(commonly derived from SV129-derived embryonic stem
cells and crossed into c57B6). However, we could not rule
out the possibility that our results are unique to the F1
hybrid B6129SF1/J strain from The Jackson Laboratory.
FIG. 1. Partial pancreatectomy (PP)–induced -cell replication in mice
at 2, 8, 12, 14, and 19 months of age. BrdU was administered for 2 weeks
after the procedure before the mice were killed. Representative pan-
creatic -cell histology of pancreas sections immunostained with anti-
bodies against insulin (red) and BrdU (green) and counterstained with
DAPI (blue) and photographed with a 40 objective. White arrows
indicate insulin and BrdU copositive cells; yellow arrows denote BrdU-
labeled non–insulin-containing cells within the islet. Scale bars: 100
m in full image and 20 m within inset. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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a similar but separate genetic cohort, Taconic Farms F1
hybrid c57 SV129 mice. Because the Jackson and Taconic
Farms lines have signiﬁcantly diverged over the years (25),
the Taconic Farms F1 hybrid c57 SV129 mice represent a
similar but genetically distinct lineage compared with
Jackson F1 hybrid B6129SF1/J mice. Consequently, the
Taconic Farms F1 hybrid c57 SV129 mice should also
approximate the mixed genetic background of laboratory
knockout mice. As previously indicated, partial pancrea-
tectomy was well tolerated in the Taconic cohort at 2 and
19 months of age. Partial pancreatectomy robustly in-
duced -cell regeneration in young Taconic mice (from
0.24  0.09 to 1.33  0.26% per day after partial pancrea-
tectomy; P  0.009) (Fig. 4). In contrast, partial pancrea-
tectomy had no effect on -cell proliferation in aged
Taconic mice (from 0.020  0.003 compared with 0.019 
0.003% per day after partial pancreatectomy; P  0.84)
(Fig. 4). These results independently conﬁrm our observa-
tions in the Jackson cohort and further illustrate that
partial pancreatectomy–induced -cell regeneration be-
comes severely restricted in aged mice. Moreover, these
additional studies indicate that our ﬁndings may be
broadly applicable to genetically engineered mice, which
frequently have a mixed c57 SV129 genetic background.
No evidence for BrdU toxicity to proliferating
-cells. Our results indicate that partial pancreatectomy–
induced -cell regeneration capacity may be severely
restricted with advanced age. However, we were con-
cerned about potential BrdU toxicity, which could theo-
retically reduce -cell proliferation. Continuous low-dose
BrdU administration in the drinking water is generally well
FIG. 2. Low-dose streptozotocin (Stz) and exendin-4 induced -cell replication in mice at 2 and 14–15 months of age. BrdU was administered for
2 weeks before the mice were killed. A: Low-dose streptozotocin. B: Exendin-4. Representative pancreatic -cell histology of pancreas sections
immunostained with antibodies against insulin (red) and BrdU (green) and counterstained with DAPI (blue) and photographed with a 40
objective. White arrows indicate insulin and BrdU copositive cells; yellow arrows denote BrdU-labeled non–insulin-containing cells within the
islet. Scale bars: 100 m in full image and 20 m within inset. (A high-quality digital representation of this ﬁgure is available in the online issue.)
FIG. 3. Quantitative analysis of -cell regeneration following partial
pancreatectomy, low-dose streptozotocin, or exendin-4 as a function of
age in mice. Results are expressed as BrdU-positive -cells (% total per
day) and represent means  SEM (n  4–6 animals per group). *P <
0.05; **P < 0.01; ***P < 0.001 sham vs. partial pancreatectomy at
various ages. P <0.05 shams at 2 months vs. shams at 12 months, 14
months, or 19 months.
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compared with short-term infusions of high-dose BrdU
(17). However, Hellerstein and colleagues (26) recently
reported that continuous BrdU administration reduces
proliferation of islet components by 25%, as measured by
heavy water incorporation into DNA. Consequently, we
tested for BrdU-associated toxicity by assessing -cell
proliferation in our cohort, as measured by the presence of
Ki67. We administered BrdU in the drinking water or
control water to a cohort of 1-month-old mice for 2 weeks,
after which they were killed. Reassuringly, Ki67-positive
-cells were equivalent in BrdU-treated and untreated
pancreata (2.29  0.31 vs. 2.51  0.25%, respectively; P 
0.59) (Fig. 5). Thus, prolonged infusion of BrdU does not
inﬂuence -cell proliferation, as measured by Ki67 expres-
sion. This result indicates that limited -cell regeneration
in aged mice cannot be readily explained by BrdU toxicity
to proliferating -cells.
Aging islets exhibit gene expression program
changes consistent with reduced cell cycle entry. To
further characterize the role of aging in adaptive -cell
proliferation capacity, we compared gene expression in
islets from young (2 months) and aged (14 months)
mice. Cyclin D2, the most abundant cyclin in islets, did
not change expression with age (supplemental Fig. 1A).
Similarly, cyclin D2 protein expression was unaltered in
aged islets compared with young islets (supplemental
Fig. 1B). Although expression of many cyclins did not
change, a few of the weakly expressing cyclins such as
D3, E1, and E2 actually increased with age (supplemen-
tal Fig. 1A). Notably, islets from aged mice had greater







(supplemental Fig. 1A). p16
Ink4a is differentially ex-
pressed in aging tissues and has been shown to restrict
islet growth (27,28). Thus, differential expression of
negative regulators of cell cycle such as p16
Ink4a or
p15
Ink4b could potentially explain the age-dependent
decline in adaptive -cell proliferation capacity. Taken
together, these results conﬁrm the observation that
partial pancreatectomy–stimulated -cell proliferation
is severely restricted in islets from aged mice.
FIG. 4. Taconic cohort. Partial pancreatectomy (PP) induced -cell
replication in mice at 2 and 19 months of age. BrdU was administered
for 2 weeks after the procedure before the mice were killed. A:
Representative pancreatic -cell histology of pancreas sections immu-
nostained with antibodies against insulin (red) and BrdU (green) and
counterstained with DAPI (blue) and photographed with a 40 objec-
tive. White arrows indicate insulin and BrdU copositive cells; yellow
arrows denote BrdU-labeled non–insulin-containing cells within the
islet. Scale bars: 100 m in full image and 20 m within inset. B:
Quantitative analysis of -cell regeneration following partial pancrea-
tectomy as a function of age in mice. Results are expressed as percent
BrdU-positive -cells per day and represent means  SEM (n  4–6
animals per group). **P < 0.01 sham vs. partial pancreatectomy at 2
months. P <0.05 shams at 2 months vs. shams at 19 months. (A
high-quality digital representation of this ﬁgure is available in the
online issue.)
FIG. 5. Low-dose-BrdU is not toxic to proliferating -cells. BrdU was
continuously administered in the drinking water for 2 weeks to a
cohort of mice aged 1 month that were then compared with untreated
control mice. A: Representative pancreatic -cell histology of pancreas
sections immunostained with antibodies against insulin (yellow), Ki67
(red), and BrdU (green) and counterstained with DAPI (blue) and
photographed with a 40 objective. White arrows indicate insulin and
BrdU copositive cells; red arrows denote insulin and Ki67 copositive
cells. Scale bars: 100 m in full image and 20 m within inset. B:
Quantitative analysis of -cell proliferation as measured by Ki67
incorporation. Continuous BrdU treatment does not slow -cell prolif-
eration. Results are expressed as percent Ki67-positive -cells and
represent means  SEM (n  5 animals per group). (A high-quality
digital representation of this ﬁgure is available in the online issue.)
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We observe that -cell regeneration is severely and
abruptly restricted by middle age in our cohort of mice.
Fifty percent partial pancreatectomy stimulated a massive
amount of -cell proliferation in young mice. However,
partial pancreatectomy had little effect on -cell prolifer-
ation in aged mice. Similarly, the -cell toxin streptozoto-
cin greatly increased -cell replication in young mice but
failed to stimulate -cell regeneration in aged mice. More-
over, -cell proliferation was stimulated by exendin-4 in
young but not in aged mice. Taken together, these results
reveal that adaptive -cell proliferation is severely re-
stricted with advanced age.
In this study, we advance the hypothesis that age is a
major factor limiting human -cell regeneration. Basal
-cell proliferation was severely reduced as a function of
age in our mice, consistent with our previous observations
(17). We further this observation to show that adaptive
-cell proliferation is also severely restricted with age. In
support of this concept, basal replication rates in human
pancreata and cultured human islets decline with donor
age (29–31). Similarly, islets from young donors have been
reported to perform better when transplanted into type 1
diabetic patients (32). Notably, type 2 diabetes is typically
a disease of the elderly, most commonly diagnosed during
middle age or beyond. Similarly, gestational diabetes mel-
litus is much more frequent with advanced maternal age
(33,34). This would imply that human patients of advanced
age could have little regenerative capacity to increase
-cell mass. Indeed, there is indirect evidence to support
this concept of an age-dependent decline in -cell regen-
eration. For instance, increased rates of diabetes have
been reported in patients after shock-wave lithotripsy for
renal stones (35). Similarly, minimal -cell regeneration is
observed in patients after partial pancreatectomy (15).
Thus, -cell regeneration could be constrained in ad-
vanced age in humans, similar to that in the aged rodents
in our study. Restricted -cell mass expansion could have
severe consequences in elderly patients with type 2 diabe-
tes, limiting compensatory -cell mass expansion to cope
with increased insulin requirements. Interestingly, several
of the recently discovered risk loci for type 2 diabetes have
been implicated in cell cycle control of -cells and could
theoretically inﬂuence adult -cell mass or alter the timing
of cell cycle exit of adult -cells (36–39).
Discrepancies between rodent and human -cell regen-
eration capacity have confounded diabetes researchers for
many years. Regeneration of -cell function in experimen-
tal animal models has been widely observed in rodents but
remains elusive and controversial in humans (13,14). No-
tably, islets from human cadaveric donors are typically in
the 4th–6th decade of life and are therefore much more
mature (32). Because our results in rodents indicate that
-cell regeneration capacity declines with age, we hypoth-
esize that young rodents may not faithfully model the
regenerative capacity of mature adult human -cells.
Our studies reveal that the regenerative capacity of
adult -cells becomes limited by early middle age (12
months of age [40% of the mouse life span]) (23). As
such, aging -cells may not be comparable with hemato-
poietic stem cells, which gradually lose replicative capac-
ity during the normal aging process (40). Under this
schema, -cells could have a developmental program that
allows them to replicate early in adulthood to match
insulin secretion capacity to peripheral insulin require-
ments. -Cell replication might then become fully re-
stricted when adult insulin requirements are established in
middle age.
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